Compare Sanofi SA (SNY) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.88. The key difference: Sanofi SA pays a 5.55% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Sanofi SA is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SNY | TMF | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $44.14 |
52-Week Low | $41.33 | $30.59 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.93 with a 0.95% daily gain. Technical indicators show a bearish trend with moving averages and ADX signaling sell conditions, while oscillators remain neutral. The ETF faces significant fundamental challenges with unavailable valuation and profitability metrics, reflecting its leveraged structure that amplifies both gains and losses in long-duration treasuries.
The outlook for TMF remains high-risk due to its daily leverage reset mechanism, making it unsuitable for long-term holdings. While some analysts see potential at bond market lows, the dominant view cautions against current purchases given the substantial erosion of value over time, with $10,000 invested five years ago now worth approximately $1,527 according to 24/7 Wall Street analysis from June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
